The last ANN we had on a commercial deal was with Prism Health in the USA & that was some years ago now, 2018 from memory & PIQ canned it & the Janssen collaboration happened. It’s been like 2 years, so no fluffy stuff for the market here, just solidly building a “Mountain of Evidence” both in the PromarkerD test & also now in treatment outcomes with Canafliglozin & SGLT2 class, and evidence built & being presented. The stock here will rise & fall on nothing & is pretty tightly held so maybe that is why?
Validation in a large clinical trial must be achieved for Key Opinion Leaders (KOL) in Endocrinology & Nephrology & now also cardiology to take this onboard & this is now happening with new Screening & Treatment Guidelines out in both the EU & USA & also treatment guidelines for Canafliglozin. (see prior posts).
It is also required to consider new testing modalities like PromarkerD, & definitely this collaboration with Janssen has been of assistance & also that the PromarkerD Immunoessay (ELISA) test that doesn’t require Mass Spectrometry testing in centralised labs with that capability, will now also make it possible for hospital labs & smaller pathology labs to process testing, without the need to send samples to Specialised Central Labs. The PromarkerD Hub is also validated by EU CE Mark & available for test interpretation both there & also by the TGA in Australia.
The test has now been validated again, in a very large post trial analysis for patients with CVD & DKD (CANVAS trial). These patients were sicker & had a commorbidity of cardiac disease or risk & the mean age was >60 years. It’s a bit different to a large community trial without significant cardiac commorbidity.
I’m really pleased about this & it’s very different to what we saw 2 years + ago.
Italy has ~3.7 million people diagnosed with diabetes, 1:12 adults. There maybe more now. COVID-19 has put a massive dent in screening & treatment for diabetes & CKD/DKD, probably CVD as well. This has been identified as a massive issue in Healthcare Policy. COVID-19 is already causing CKD/DKD in otherwise well recovered people with or without Diabetes, we already know this is a risk factor for severe disease. I think that was the point @betheball was trying to get across & it’s correct.
GLTAH
PIQ Price at posting:
56.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)